Truist Securities Maintains Hold on Harmony Biosciences Hldgs, Raises Price Target to $29

Benzinga Newsdesk www.benzinga.com Positive 85.4%

Neg 0% Neu 0% Pos 85.4%

Truist Securities analyst Danielle Brill maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Hold and raises the price target from $25 to $29.